8:50 am Chair’s Opening Remarks

Determine the Therapeutic Potential of JAK Inhibitors for Dermatological Disease

9:00 am The Emerging Evidence for the Use of JAK Inhibitors in Connective Tissue Diseases (CTDs)

  • Mehdi Rashighi Director, Connective Tissue Disease Clinic & Research Center, University of Massachusetts Medical School

Synopsis

  • Detailing the basic science and rationale
  • Providing anecdotal evidence and case reports
  • Updating and describing ongoing clinical trials

9:25 am The Evolving Landscape of JAK Inhibitors for Chronic Itch

  • Brian Kim Co-Director, Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine

Synopsis

  • Introduce scientific findings related to how JAKs mediate itch
  • Overview of itch outcomes in AD trials
  • New clinical studies on new indications for cytokine blockade and JAK inhibition in chronic itch

9:50 am Targeting JAK Signalling in the Treatment of Vitiligo

  • Fiona Kuo Director, Inflammation & Autoimmunity Clinical Development, Incyte

Synopsis

  • Overview of vitiligo pathogenesis, psychosocial comorbidities and unmet medical need
  • Discuss vitiligo competitive landscape, current challenges in conducting vitiligo clinical trials and regulatory path
  • Demonstrate efficacy and safety of ruxolitinib (JAK inhibitor) cream and discuss subgroup analysis based on patient demographics and clinical characteristics from a phase 2 vitiligo clinical trial

10:15 am Update on Long-Term Safety & Efficacy of CTP-543, an Oral JAK Inhibitor, for the Treatment of Alopecia Areata

  • Jim Cassella Chief Development Officer, Concert Pharmaceuticals

Synopsis

  • CTP-543 was dosed for 24 weeks in three Phase 2 trials; eligible patients subsequently enrolled in a long-term, open-label extension trial with >130 patients treated for more than 1 year.
  • Hair regrowth assessed by SALT has been sustained or improved in the vast majority of patients in the extension study relative to the Phase 2 results
  • Treatment with CTP-543 continues to be generally well tolerated, with a safety profile similar to that observed in Phase 2.

10:40 am Speaker Q&A panel

  • Mehdi Rashighi Director, Connective Tissue Disease Clinic & Research Center, University of Massachusetts Medical School
  • Brian Kim Co-Director, Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine
  • Fiona Kuo Director, Inflammation & Autoimmunity Clinical Development, Incyte
  • Jim Cassella Chief Development Officer, Concert Pharmaceuticals

11:00 am Virtual Speed Networking

11:30 am Coffee Break

11:40 am The Dual Inhibition of SYK & JAK Kinases for the Treatment of Skin & Complex Inflammatory Conditions

  • Sandeep Gupta President & Chief Executive Officer, Asana BioSciences

Synopsis

  • Addressing novel treatments in Chronic Hand Eczema as therapy gusacitinib, a dual SYK/JAK inhibitor, advances to phase 3 clinical development.
  • Evaluating additional role of TYK2 and SYK in epithelial cell/keratinocyte function
  • Detailing further potential in dermatologic and immunologic condition

12:05 pm A Model for Polyautoimmune & Inflammatory Disease & its Treatment with JAK Inhibitors

  • Brett King Associate Professor of Dermatology, Yale University School of Medicine

Synopsis

  • Addressing the poorly understood treatment of patients with multiple autoimmune and inflammatory diseases
  • Developing a model for polyautoimmune and inflammatory disease and its treatment
  • Describing the potential of JAK inhibitors for the treatment of complex patients with polyautoimmune and inflammatory disease

12:30 pm Speaker Q&A panel

  • Brett King Associate Professor of Dermatology, Yale University School of Medicine
  • Sandeep Gupta President & Chief Executive Officer, Asana BioSciences

12:40 pm Lunch

Highlighting the Efficacious & Widely Applicable JAK Inhibitor in Other Specialities to Provide Wider Clinical Insight

1:40 pm Exploring the Role of JAK Inhibition in the Treatment of Sarcoidosis & Other Granulomatous Disorders

  • William Damsky Assistant Professor in Dermatology & Dermatopathology, Yale School of Medicine

Synopsis

  • Addressing the difficulties in treating granulomatous inflammatory disorders, including sarcoidosis
  • There is emerging evidence that JAK inhibition may be a promising treatment approach in sarcoidosis, granuloma annulare, and other granulomatous disorders
  • Efficacy data and key cytokine targets of JAK inhibitors in sarcoidosis and other granulomatous disorders will be discussed

2:05 pm An Overview of JAKi in Rheumotology

  • Massimo Gadina Director & Chief of Translational Immunology Section, Science & Technology, NIAMS/NIH

Synopsis

  • Historical overview of how JAK inhibitors were developed.
  • Review of first-generation pan-JAK inhibitors and their current clinical application
  • JAK-selective, second-generation JAK inhibitors: what is there already and what is arriving.
  • The effect of JAK inhibitors on circulating immune cell

2:30 pm Speaker Q&A panel

  • William Damsky Assistant Professor in Dermatology & Dermatopathology, Yale School of Medicine
  • Massimo Gadina Director & Chief of Translational Immunology Section, Science & Technology, NIAMS/NIH

2:40 pm Break

3:10 pm Reistone Biopharma’s Pursuit into Ulcerative Colitis Using a – JAK 1 Inhibitor – a Successful Case Study

  • Aik Han Goh Chief Medical Officer, Reistone Biopharma

Synopsis

  • Describing the latest RSJ10101 results from in UC therapy
  • Defining the drug MOA, clinical endpoints used, and overcoming operational challenges in a UC study
  • Looking forward towards future studies and correlating progress with other disease

3:35 pm Momelotinib as a Differentiated JAK / ACBR – ACBR 1 Inhibition

Synopsis

  • Describing the significant unmet needs in myelofibrosis include the need for durable benefits and longer survival, improved anemia and transfusion requirements, and benefit in patients with thrombocytopenia
  • Detailing how potent inhibition of ACVR1, in addition to JAK1 and JAK2 inhibition, can reduce or eliminate the need for transfusion, potentially leading to improved overall survival
  • Based on the differentiated hematologic safety profile, momelotinib has the potential to become a combination agent of choice

4:00 pm Speaker Q&A panel

4:10 pm Chair’s Closing Remarks